CV Therapeutics’ Pre-"Approvable" Letter To FDA’s Temple
This article was originally published in Pharmaceutical Approvals Monthly
Excerpts from an Oct. 20, 2003 letter to Office of Drug Evaluation I Director Robert Temple. CV Therapeutics CEO Robert Lange and VP-Clinical R&D Andrew Wolff proposed a risk management program (ultimately not instituted upon approval) and downplayed QT concerns regarding Ranexa. FDA issued an "approvable" letter ten days later.
You may also be interested in...
Large outcomes studies "will be the wave of the future for many products, not just cardiovascular products," CV Therapeutics CEO Louis Lange predicted during a Feb. 8 earnings call.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011